Cargando…
IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715677/ http://dx.doi.org/10.1093/neuonc/noaa222.346 |
_version_ | 1783619011047587840 |
---|---|
author | Tam, Lydia Han, Michelle Wright, Jason Toescu, Sebastien Campion, Andrew Shpanskaya, Katie Mankad, Kshitij Ho, Chang Lober, Robert Cheshier, Samuel Hargrave, Darren Jacques, Tom Aquilina, Kristian Monje, Michelle Grant, Gerald Mattonen, Sarah Vitanza, Nick Yeom, Kristen |
author_facet | Tam, Lydia Han, Michelle Wright, Jason Toescu, Sebastien Campion, Andrew Shpanskaya, Katie Mankad, Kshitij Ho, Chang Lober, Robert Cheshier, Samuel Hargrave, Darren Jacques, Tom Aquilina, Kristian Monje, Michelle Grant, Gerald Mattonen, Sarah Vitanza, Nick Yeom, Kristen |
author_sort | Tam, Lydia |
collection | PubMed |
description | BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentation. METHODS: 104 treatment-naïve DMG MRIs from five centers were used (median age=6.5yrs; 18 males, median OS=11mos). We isolated tumor volumes of T1-post-contrast (T1gad) and T2-weighted (T2) MRI for PyRadiomics high-dimensional feature extraction. 900 features were extracted on each image, including first order statistics, 2D/3D Shape, Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Neighboring Gray tone Difference Matrix, and Gray Level Dependence Matrix, as defined by Imaging Biomarker Standardization Initiative. Overall survival (OS) served as outcome. 10-fold cross-validation of LASSO Cox regression was used to predict OS. We analyzed model performance using clinical variable (age at diagnosis and sex) only, radiomics only, and radiomics plus clinical variable. Concordance metric was used to assess the Cox model. RESULTS: Nine radiomic features were selected from T1gad (2 texture wavelet) and T2 (5 first-order features (1 original, 4 wavelet), 2 texture features (1 wavelet, 1 log-sigma). This model demonstrated significantly higher performance than a clinical model alone (C: 0.68 vs 0.59, p<0.001). Adding clinical features to radiomic features slightly improved prediction, but was not significant (C=0.70, p=0.06). CONCLUSION: Our pilot study shows a potential role for MRI-based radiomics and machine learning for DMG risk stratification and as image-based biomarkers for clinical therapy trials. |
format | Online Article Text |
id | pubmed-7715677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77156772020-12-09 IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA Tam, Lydia Han, Michelle Wright, Jason Toescu, Sebastien Campion, Andrew Shpanskaya, Katie Mankad, Kshitij Ho, Chang Lober, Robert Cheshier, Samuel Hargrave, Darren Jacques, Tom Aquilina, Kristian Monje, Michelle Grant, Gerald Mattonen, Sarah Vitanza, Nick Yeom, Kristen Neuro Oncol Imaging BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentation. METHODS: 104 treatment-naïve DMG MRIs from five centers were used (median age=6.5yrs; 18 males, median OS=11mos). We isolated tumor volumes of T1-post-contrast (T1gad) and T2-weighted (T2) MRI for PyRadiomics high-dimensional feature extraction. 900 features were extracted on each image, including first order statistics, 2D/3D Shape, Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Neighboring Gray tone Difference Matrix, and Gray Level Dependence Matrix, as defined by Imaging Biomarker Standardization Initiative. Overall survival (OS) served as outcome. 10-fold cross-validation of LASSO Cox regression was used to predict OS. We analyzed model performance using clinical variable (age at diagnosis and sex) only, radiomics only, and radiomics plus clinical variable. Concordance metric was used to assess the Cox model. RESULTS: Nine radiomic features were selected from T1gad (2 texture wavelet) and T2 (5 first-order features (1 original, 4 wavelet), 2 texture features (1 wavelet, 1 log-sigma). This model demonstrated significantly higher performance than a clinical model alone (C: 0.68 vs 0.59, p<0.001). Adding clinical features to radiomic features slightly improved prediction, but was not significant (C=0.70, p=0.06). CONCLUSION: Our pilot study shows a potential role for MRI-based radiomics and machine learning for DMG risk stratification and as image-based biomarkers for clinical therapy trials. Oxford University Press 2020-12-04 /pmc/articles/PMC7715677/ http://dx.doi.org/10.1093/neuonc/noaa222.346 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Imaging Tam, Lydia Han, Michelle Wright, Jason Toescu, Sebastien Campion, Andrew Shpanskaya, Katie Mankad, Kshitij Ho, Chang Lober, Robert Cheshier, Samuel Hargrave, Darren Jacques, Tom Aquilina, Kristian Monje, Michelle Grant, Gerald Mattonen, Sarah Vitanza, Nick Yeom, Kristen IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title | IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title_full | IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title_fullStr | IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title_full_unstemmed | IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title_short | IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA |
title_sort | img-10. mri-based radiomic prognostic markers of diffuse midline glioma |
topic | Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715677/ http://dx.doi.org/10.1093/neuonc/noaa222.346 |
work_keys_str_mv | AT tamlydia img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT hanmichelle img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT wrightjason img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT toescusebastien img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT campionandrew img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT shpanskayakatie img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT mankadkshitij img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT hochang img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT loberrobert img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT cheshiersamuel img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT hargravedarren img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT jacquestom img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT aquilinakristian img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT monjemichelle img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT grantgerald img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT mattonensarah img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT vitanzanick img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma AT yeomkristen img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma |